Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrops for glaucoma. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Frequently asked questions
What sector does Q BioMed Inc (QBIO) operate in?
Q BioMed Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Q BioMed Inc (QBIO) current stock price?
As of the latest data, Q BioMed Inc stock price is $0.00, with a previous close of $0.00.
What is Q BioMed Inc (QBIO) current market capitalization?
Q BioMed Inc market cap is approximately 14.51 thousand.
What is Q BioMed Inc (QBIO) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
Does Q BioMed Inc (QBIO) pay dividends?
No. Q BioMed Inc does not pay a dividend.
What is Q BioMed Inc (QBIO) beta (volatility) score?
Q BioMed Inc has a beta of 184.641, indicating very high volatility compared to the market.